VERAXA Biotech Expands Heidelberg R&D by Over 60% for BiTAC Programs
VRXA•VERAXA Biotech has expanded its Heidelberg R&D site by over 60% to accommodate new laboratory infrastructure, team additions and specialized equipment installations. This enlargement accelerates the development of its proprietary BiTAC-TCE and BiTAC-ADC cancer therapy programs toward early clinical stages, leveraging the region’s oncology research cluster.
1. Expansion of Heidelberg R&D Facility
The company increased its existing Heidelberg laboratory space by more than 60% under a long-term lease agreement, enabling installation of new specialized equipment and accommodation for planned R&D headcount growth.
2. Advancing BiTAC-TCE and BiTAC-ADC Programs
Expanded infrastructure supports the advancement of proprietary BiTAC-TCE and BiTAC-ADC development programs, which are moving from discovery toward planned early clinical development stages.
3. Strategic Benefits of Heidelberg Cluster
Located within a leading biopharmaceutical cluster, the enlarged site offers enhanced collaboration with academia and oncology research organizations while maintaining uninterrupted R&D operations.
